EmailStory Stocks®
Archive
Last Update: 08-Nov-11 14:25 ET
Medtronic Reports Positive Endeavor Results
Medtronic (MDT $34.95 -0.10) reported that study of its Endeavor drug-eluting stent demonstrates long-term advantages over Boston Scientific's (BSX) Taxus DES.
New research findings released at TCT 2011 show that the Endeavor zotarolimus-eluting stent (DES) from Medtronic, outperformed Boston Scientific Corp.'s Taxus paclitaxel-eluting stent on standard measures of safety and efficacy through five years of clinical follow-up.
The findings come from ENDEAVOR IV, a randomized trial involving nearly 1,550 patients with coronary artery disease that compared the two drug-eluting stents head-to-head.
New research findings released at TCT 2011 show that the Endeavor zotarolimus-eluting stent (DES) from Medtronic, outperformed Boston Scientific Corp.'s Taxus paclitaxel-eluting stent on standard measures of safety and efficacy through five years of clinical follow-up.
The findings come from ENDEAVOR IV, a randomized trial involving nearly 1,550 patients with coronary artery disease that compared the two drug-eluting stents head-to-head.
